1 to 9 of 10 results

Daiichi Sankyo seeks wider indication for Cravit in Japan

Daiichi Sankyo seeks wider indication for Cravit in Japan


Japanese drug major Daiichi Sankyo has submitted a supplemental New Drug Application (sNDA) in Japan…

Antibiotics and Infectious diseasesCravitDaiichi SankyoJapanPharmaceuticalRegulation

US FDA pulls 27 Ranbaxy ANDAs approvals under consent decree


The Food and Drug Administration is withdrawing approval of 27 Abbreviated New Drug Applications (ANDAs)…

Antibiotics and Infectious diseasesDaiichi SankyoDiabetesGenericsNorth AmericaRanbaxy LaboratoriesRegulation

Daiichi Sankyo and Terumo link up for vaccine development


Drug major Daiichi Sankyo (TYO: 4568) and fellow Japanese company Terumo Corp (TYO: 4543) have entered…

Antibiotics and Infectious diseasesDaiichi SankyoPharmaceuticalResearchTerumoVaccines

Additional indications in Japan for Diagnogreen and Sawacillin


Japanese drug major Daiichi Sankyo (TYO: 4568) says it has received approval in Japan for a supplemental…

Antibiotics and Infectious diseasesAsia-PacificAstellas PharmaDaiichi SankyoPharmaceuticalRegulationSawacillin

Backing for Japanese approval of Regnite, Ranmark and Cancidas


USA-based XenoPort (Nasdaq: XNPT) saw its shares rise 3% to $4.73 on Friday, when the company said it…

Antibiotics and Infectious diseasesAsia-PacificCancidasDaiichi SankyodenosumabHorizantMerck & CoOncologyPharmaceuticalRegniteRegulationXenoPort

Ranbaxy to market four drugs for Daiichi Sankyo in Singapore


Japan’s second largest drugmaker, Daiichi Sankyo TYO: 4568), has announced the start of synergistic…

Antibiotics and Infectious diseasesAsia-PacificCravitDaiichi SankyoMarkets & MarketingPharmaceuticalRanbaxy Laboratories

Daiichi Sankyo launches flu drug Inavir inhaler in Japan; expands deal with ArQule; gets favorable patent ruling against Lupin


Japanese drug major Daiichi Sankyo (TSE 4568) yesterday launched its anti-influenza treatment Inavir…

Anti-viralsAntibiotics and Infectious diseasesArQuleBiota HoldingsDaiichi SankyoGenericsInavirLegalLevofloxacinLupinOncologyPharmaceuticalRegulationResearch

Daiichi Sankyo to leverage Ranbaxy’s Romania and South Africa presence to market Tavanic


Japanese drug major Daiichi Sankyo says it plans to leverage its 64%-owned Indian affiliate Ranbaxy Laboratories’…

Antibiotics and Infectious diseasesDaiichi SankyoEuropeLicensingMarkets & MarketingPharmaceuticalRanbaxy LaboratoriesRest of the WorldSanofi-AventisTavanic

1 to 9 of 10 results



Back to top